
Viatris Unveils Late-Breaking Abstract on Cenerimod at the 26th APLAR Annual Congress
Viatris Inc. (NASDAQ: VTRS), a leading global healthcare company, today presented results from its Phase 2 study of cenerimod (ACT-333441) as a late-breaking abstract at the 26th Asia-Pacific League of…













